24 recruiting. 24 Phase 2, 4 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Recruiting 24 |
| Phase 1 | 4 | Recruiting 4 |
| Phase 3 | 4 | Recruiting 4 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock istaroxime, placebo - Cardiogenic Shock | Phase 2 / Phase 3 | Recruiting | Seismic Pharmaceuticals Operations LLC | 600 | 2026-09-09 | 2026-09-23 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Adjunctive Fludrocortisone in Septic Shock Fludrocortisone 100 mcg daily, Placebo - Sepsis, Septic Shock | Phase 2 | Recruiting | Chinese University of Hong Kong | 32 | 2026-04-01 | 2026-06-02 |
| Early Methylene Blue in the Microhemodynamics of Septic Patients Methylene blue infusion - Septic Shock, Hypoperfusion | Phase 2 / Phase 3 | Recruiting | Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva | 50 | 2026-01-09 | 2026-03-27 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma Siltuximab - CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. AK1967 (Invobenitug also known as Procizumab), Placebo - Shock, Cardiogenic | Phase 1 / Phase 2 | Recruiting | 4TEEN4 Pharmaceuticals GmbH | 90 | 2025-07-13 | 2026-09-14 |
| Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System Cardiohelp device (VA-ECMO), Heparin, Bivalirudin - Heart Failure, Cardiogenic Shock | Phase 2 | Recruiting | Stanford University | 50 | 2025-04-15 | 2026-08-10 |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma Elranatamab injection - Refractory Multiple Myeloma | Phase 2 | Recruiting | Ontario Clinical Oncology Group (OCOG) | 40 | 2025-03-28 | 2026-09-28 |
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL Obinutuzumab, Glofitamab, Gemcitabine - Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma | Phase 2 | Recruiting | Hoffmann-La Roche | 130 | 2025-03-05 | 2026-10-09 |
| Pulse Study: Peripheral Use of Low-dose Vasopressors for Safety and Efficacy in the Intensive Care Unit Experiemental: Peripheral Venous Catheter - Shock, Peripheral Venous Catheterization | Phase 2 | Recruiting | Kingston Health Sciences Centre | 50 | 2025-02-03 | 2025-04-09 |
| Study SOLACE SEPSIS Sodium Lactate, 3% NaCl - Septic Shock, Intracranial Hypertension | Phase 2 | Recruiting | University Hospital Pilsen | 40 | 2024-11-24 | 2026-04-14 |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) Placebo comparator, PRS CK STORM - SARS-CoV-2, Influenza, Human | Phase 1 / Phase 2 | Recruiting | PEACHES BIOTECH | 50 | 2024-10-02 | 2026-06-10 |
| Physiology of Unloading VA ECMO Trial IABP - Cardiogenic Shock | Phase 2 | Recruiting | University of Utah | 104 | 2024-10-02 | 2026-04-30 |
| Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days, Protonix (pantoprazole) 40 mg q 24 hrs for 2 days - Acute Kidney Injury | Phase 2 / Phase 3 | Recruiting | The University of Texas Health Science Center, Houston | 100 | 2024-09-07 | 2026-02-19 |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial Calcium Gluconate, Vasopressin, saline placebo - Trauma, Hemorrhage | Phase 2 | Recruiting | Jason Sperry | 1050 | 2024-06-30 | 2026-10-30 |
| Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO Cangrelor - Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication | Phase 2 | Recruiting | IRCCS San Raffaele | 50 | 2024-04-01 | 2025-01-27 |
| Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock Allogeneic umbilical cord-derived human mesenchymal stromal cells, Placebo - Septic Shock, Sepsis | Phase 2 | Recruiting | Ottawa Hospital Research Institute | 296 | 2024-02-14 | 2024-12-05 |
| Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg - Cytokine Release Syndrome | Phase 1 / Phase 2 | Recruiting | CytoAgents, Inc. | 54 | 2023-12-28 | 2026-08-31 |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma Teclistamab, Talquetamab, Tocilizumab - Multiple Myeloma | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2023-10-23 | 2026-04-22 |
Showing 20 of 24. Sign in to see all of them.
Cytokine Release Syndrome (8) · Shock, Septic (7) · Shock, Cardiogenic (5) · Sepsis (4) · Multiple Myeloma (3) · Recurrence (3) · Systemic Inflammatory Response Syndrome (3) · COVID-19 (2) · Inflammation (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Pneumonia (2) · Shock, Hemorrhagic (2) · Acute Coronary Syndrome (1)
Pathological Conditions, Signs and Symptoms (24) · Pathologic Processes (23) · Inflammation (14) · Systemic Inflammatory Response Syndrome (13) · Infections (9) · Cardiovascular Diseases (8) · Vascular Diseases (8) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Heart Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Infarction (5)
talquetamab (2) · Biopsy (1) · CT-P13 (1) · Calcium Dobesilate (1) · Calcium Gluconate (1) · Dexamethasone (1) · Fludrocortisone (1) · Gemcitabine (1) · Heparin (1) · Infliximab (1) · Istaroxime (1) · Magnetic Resonance Spectroscopy (1) · Methylene Blue (1) · Oxaliplatin (1) · Pantoprazole (1)
4TEEN4 Pharmaceuticals GmbH (1) · Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva (1) · Chinese University of Hong Kong (1) · CytoAgents, Inc. (1) · Health Institutes of Turkey (1) · Hoffmann-La Roche (1) · Hospital General Universitario Gregorio Marañon (1) · IRCCS San Raffaele (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jason Sperry (1) · Kingston Health Sciences Centre (1) · Medical University of Lublin (1) · Naresh Bumma (1) · Ontario Clinical Oncology Group (OCOG) (1) · Ottawa Hospital Research Institute (1)
United States (8) · Canada (5) · Germany (3) · Spain (3) · Armenia (2) · Czechia (2) · France (2) · Italy (2) · Poland (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · Hong Kong (1)
Alexandre Mebazaa, Professor (1) · Caroline Ozment, MD (1) · David A. Morrow, MD, MPH (1) · David Bernal, Dr. (1) · Emily Rimmer, MD, MSc (1) · Gabe Coitler (1) · Gernot Marx, Univ.-Prof. (1) · Gord Dr., PhD, MD (1) · Hira Mian, MD (1) · Jason Sperry, MD (1) · Jim Wright, MD (1)
PMID 15231405, PMID 16134000, PMID 21093515, PMID 21659748, PMID 23036432, PMID 24200239, PMID 24329115, PMID 28188927, PMID 28234482, PMID 29906742, PMID 30832742, PMID 33231055, PMID 33517187, PMID 34170599, PMID 34398408, PMID 34830015, PMID 35454123, PMID 35857130, PMID 36074228, PMID 36378586, PMID 36508996, PMID 37406514, PMID 37520007, PMID 37954118, PMID 42165327
2016 (1), 2023 (1), R44CA295189 (1)